Project Grant HT94252310992
Award Date
9/30/23
Completion Date
9/29/27
Dollars Obligated
$3.2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98105, USA
Similar Awards
This Project Grant award of $434,993 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Children's Hospital Los Angeles. The funding supports research using high-throughput sequencing of the immunoglobulin loci to develop refined risk stratification methods for pediatric B-cell acute lymphoblastic leukemia (B-ALL). The project aims to advance understanding and treatment of this pediatric cancer, with an expected completion...
The Defense Health Agency awarded a $1,528,727.00 Project Grant to Children's Research Institute, a subsidiary of Children's National Medical Center, to develop SGT-53, a novel nanomedicine that crosses the blood-brain barrier and augments immunotherapeutic response in pediatric brain cancers. This grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports basic, applied, and advanced biomedical research to transform healthcare for Service Members and the...
The Department of the Army Medical Command awarded a $1,416,000 project grant to Boston Children's Hospital under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research to define leukemia stem cells in acute lymphoblastic leukemia from September 2021 through September 2025. Through this funding, Boston Children's Hospital researchers will investigate medical solutions for the battlefield by transforming healthcare for service members and the public. The...
The Children's Research Institute received a $709,638 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research efforts from May 2021 through April 2024 to enhance T-cell immunotherapy treatments for pediatric patients with relapsed or refractory solid tumors. The Military Medical Research and Development program supports biomedical research that transforms military and public health...
The Defense Health Agency awarded a $1,000,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Children's Hospital Corporation, doing business as Boston Children's Hospital, to support research on the "Diversity of Memory B Cells in Lupus". The 4-year grant, with a period of performance from September 1, 2024 to August 31, 2028, will enable Boston Children's Hospital to conduct biomedical research focused on understanding the role of...
The Department of Defense's Defense Health Agency awarded a $393,800 Project Grant to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, to conduct research on "Elucidating Mechanisms of Cell Death in Plasmodium Vivax-Infected Hepatocytes." This grant, provided through the Military Medical Research and Development program (CFDA 12.420), supports basic, translational, and clinical research aimed at developing new treatments, improving patient care, and...
This $695,464 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to map the causal variants and mechanisms underlying genetic predisposition to childhood B-cell acute lymphoblastic leukemia (B-ALL). The award to Boston Children's Hospital will integrate results from a multi-ancestry genome-wide association study (GWAS) with single-cell epigenomic data to pinpoint causal variants at known B-ALL risk loci. The team will then use...
The Project Grant award of $624,000 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program to the Research Institute at Nationwide Children's Hospital. The funding supports a project titled "SPLICING UP PD-L1 FOR IMMUNOTHERAPY ENHANCEMENT IN PEDIATRIC NEURONAL TUMORS" over a two-year period from September 30, 2023 to September 29, 2025. The goal is to conduct research to advance immunotherapy approaches...
This Project Grant award for $616,710.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the Children's Research Institute in Washington, D.C. in designing effective adoptive immunotherapy for high-risk pediatric medulloblastoma. The research aims to develop a rational combination with MRI-guided focused ultrasound technology to enhance this innovative cancer treatment approach. The award period runs from August 1, 2024...
The Department of the Army Medical Command awarded a $2,247,531 project grant to The Children's Hospital of Philadelphia through the Military Medical Research and Development program (CFDA 12.420) to conduct a comprehensive evaluation of immune function in patients receiving multimodal therapy for high-risk neuroblastoma. The four-year project beginning September 1, 2022 will apply basic, applied, and advanced biomedical research approaches to transform pediatric cancer care and investigate...